- Notice: Medical Device Single Audit Program (MDSAP) Reduction of Audit Times
- Notice: Publication of the Guidance Document: Guidance for Manufacturers of Human Immunodeficiency Virus (HIV) Rapid Diagnostic Tests (RDTs) for use at the Point of Care or for Self-Testing
- Guidance: General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products
- Guidance: Recommended Statement for Over the-Counter Aspirin-Containing Drug Products Labeled With Cardiovascular Related Imagery
- Guidance Document: Addendum - Quality (Chemistry and Manufacturing) Guidance: Questions and Answers
- Updated Notice: Interim Policy on Health Canada's Interpretation of Medicinal Ingredient and Assessment of Identical Medicinal Ingredient
- Notice: Validation rules for regulatory transactions submitted to Health Canada in the electronic Common Technical Document (eCTD) format
- Notice: General Chapters <232> Elemental Impurities–Limits and <2232> Elemental Contaminants in Dietary Supplements Applicable as of January 1, 2018
- Consultation on the Proposed Approach to the Regulation of Cannabis
- Proposed Approach to the Regulation of Cannabis